Narrative review suggests gluten-free diet may help Hashimoto's in Celiac patients but evidence is insufficient for universal use

Photo by Toa Heftiba / Unsplash

Frontiers in Medicine Published May 4, 2026 Medically reviewed May 4, 2026 DOI ↗ By Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

Key Takeaway

Consider targeted screening and individualized counseling for gluten-free diet in Hashimoto's patients rather than universal restriction

This narrative review evaluates the impact of a gluten-free diet (GFD) on patients with Celiac disease, Hashimoto's thyroiditis, or both. The scope includes assessing whether gluten acts as a universal trigger or merely a candidate modifier in Hashimoto's thyroiditis. The authors emphasize that causality is not established for all cases.

The primary synthesized finding indicates that patients with comorbid Celiac disease and Hashimoto's thyroiditis may gain indirect thyroid-related benefits as intestinal inflammation improves. However, the review concludes that evidence remains insufficient to recommend routine gluten withdrawal for all patients with non-celiac Hashimoto's thyroiditis. No specific effect sizes or absolute numbers were reported for these outcomes.

The authors highlight that long-term GFD carries practical and nutritional burdens that require professional supervision. Limitations include the insufficient evidence to support universal gluten restriction and the lack of reported data on adverse events or specific study populations. The review suggests targeted screening for Celiac disease or other gluten-related disorders in selected Hashimoto's patients, followed by individualized dietary counseling rather than universal restriction.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedMay 2026

View Original Abstract ↓

Celiac disease (CD) and Hashimoto’s thyroiditis (HT) frequently coexist, suggesting that shared mechanisms of autoimmunity extend beyond the intestine. In CD, the pathogenic role of gluten is firmly established; in HT, however, gluten is better viewed as a candidate modifier rather than a proven universal trigger. This review synthesizes current evidence on how gluten may influence the CD-HT axis through gut dysbiosis, epithelial barrier dysfunction, immune cross-reactivity, and epigenetic regulation. We also examine the clinical evidence for gluten-free diet (GFD) use in three settings: classical CD, CD-HT comorbidity, and HT without confirmed CD. Current data support lifelong GFD in CD and suggest that patients with both CD and HT may gain indirect thyroid-related benefit as intestinal inflammation improves. By contrast, evidence remains insufficient to recommend routine gluten withdrawal for all patients with non-celiac HT. Long-term GFD also carries practical and nutritional burdens that require professional supervision. Overall, the most defensible clinical approach is targeted screening for CD or other gluten-related disorders in selected HT patients, followed by individualized dietary counseling rather than universal restriction. Future work should prioritize mechanistically informed, adequately powered randomized trials to identify which thyroid-autoimmune phenotypes, if any, are most likely to benefit from gluten exclusion.